Immunovant, Inc. IMVT Business Segments — Acquired in-process research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s business segments — acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s business segments — acquired in-process research and development?
- Immunovant, Inc. (IMVT) reported business segments — acquired in-process research and development of $0 in Q1 2026.
- What is the long-term trend for Immunovant, Inc.'s business segments — acquired in-process research and development?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — acquired in-process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $10M to $0.
- What does business segments — acquired in-process research and development mean?
- Refers to the value assigned to research and development projects acquired through business combinations or asset purchases that have not yet reached technological feasibility. These costs represent the upfront investment in external intellectual property or pipeline assets that are still in the development phase. Monitoring this helps investors understand the company's strategy for inorganic growth and pipeline expansion.